Investment & Growth Strategy - Apollo plans to double its assets under management (AUM) in India to $4 billion over the next three years [1] Market Opportunity - Apollo aims to capitalize on the booming private credit market in India [1]

Private-capital giant Apollo and finance firm ACS have devised a remarkably complicated fund that is finding creative ways to put insurance capital to work https://t.co/h3DWPyWmNQ ...

Core Viewpoint - The innovative pharmaceutical sector is experiencing significant growth in the Hong Kong and A-share markets, driven by policy benefits, accelerated trends in overseas expansion, and continuous capital investment, with companies like Dongyangguang Pharmaceutical gaining investor attention due to their strong performance and potential [1][9]. Group 1: Company Overview - Dongyangguang Pharmaceutical successfully listed on the Hong Kong main board on August 7, 2023, through a unique "absorption merger + introduction" method, marking a new paradigm for asset securitization among Chinese innovative pharmaceutical companies [1]. - The company has a robust research and development team of over 1,100 personnel, including experienced scientists and industry veterans, which positions it among the top tier in the industry [2][3]. Group 2: Product Pipeline and R&D Strength - Dongyangguang Pharmaceutical has established a comprehensive R&D platform over 20 years, focusing on advanced technologies such as small molecule targeted drugs, AIDD, ADC, and AI-driven models to enhance efficiency and innovation [3]. - The company currently has 150 approved drugs globally and over 100 drugs in development, including 49 first-class innovative drugs, showcasing a rich product pipeline with significant commercial potential [3][4]. Group 3: Market Performance and Financials - Following the absorption merger, Dongyangguang Pharmaceutical's stock price initially dropped but rebounded, indicating strong market recognition of its true value and growth potential, with a market cap target of reaching hundreds of billions [2][9]. - The company has seen a substantial increase in revenue from chronic disease treatment drugs, with projections showing a rise from 517 million to 1.068 billion yuan from 2022 to 2024, reflecting a shift towards a dual growth model driven by both infection and chronic disease treatments [6]. Group 4: Strategic Partnerships and International Expansion - Dongyangguang Pharmaceutical has engaged in significant international collaborations, including a nearly $1 billion licensing agreement with UK-based Apollo for its HEC88473 project, indicating strong recognition of its R&D capabilities [5]. - The company has developed a global sales network, covering major markets including the US and Europe, which enhances its commercialization capabilities and market reach [6]. Group 5: Future Outlook - With a rich product pipeline and several drugs with billion-dollar commercialization potential set to launch, Dongyangguang Pharmaceutical is positioned for substantial growth, making it an attractive opportunity for long-term investors [9].

Core Viewpoint - The innovative pharmaceutical sector has emerged as one of the strongest directions in the Hong Kong and A-share markets this year, driven by policy benefits, accelerated trends in overseas expansion of innovative drugs, and continuous capital investment [1] Group 1: Company Overview - Dongyangguang Pharmaceutical successfully listed on the Hong Kong main board on August 7, 2023, through a unique "absorption merger + introduction" method, marking a new paradigm for asset securitization among Chinese innovative pharmaceutical companies [1] - The company has a robust research and development team with over 1,100 personnel, including experienced scientists from multinational pharmaceutical companies [2] - Dongyangguang Pharmaceutical has established a comprehensive R&D platform and technical system over 20 years, covering various advanced technology fields [3] Group 2: Product Pipeline and Market Potential - The company currently has 150 approved drugs globally and over 100 drugs in development, including 49 first-class innovative drugs, showcasing a rich product reserve with several candidates having billion-dollar commercialization potential [3] - In the diabetes sector, Dongyangguang's insulin product is expected to be the first in China to be approved in the U.S. without phase III clinical trials, while its cancer drug has significant market potential with projected peak sales of $1 billion [4][5] - The company has seen a substantial increase in revenue from chronic disease treatment drugs, with projections indicating a rise from 5.17 billion yuan in 2022 to 10.68 billion yuan in 2024, nearly doubling its share of total revenue [6] Group 3: Strategic Developments - Dongyangguang Pharmaceutical has engaged in international licensing agreements, including a nearly $1 billion deal with Apollo for its HEC88473 project, indicating strong recognition of its R&D capabilities [5] - The company has a comprehensive production and sales network, with manufacturing bases that meet international standards and a sales network covering over 32 provinces in China and several countries abroad [6] - Following the merger with Dongyangguang Changjiang Pharmaceutical, the company has created a closed-loop system integrating R&D, production, and sales, enhancing its competitive advantage and accelerating new drug launches [7] Group 4: Future Outlook - With the ongoing advancement of its product pipeline and the expected launch of several new drugs with billion-dollar commercialization potential, Dongyangguang Pharmaceutical is poised for significant growth, aiming for a market capitalization of 100 billion yuan [9]

Galaxy, Apollo, and Fidelity are not only investing in Plume, they’re actively deploying capital and issuing assets.$360M TVL and 177K RWA holders in weeks is just the beginning for $PLUME 🚀 https://t.co/OQk1daAOks ...

We've had reporting from Bloomberg this morning suggesting that £5 billion of Europe's football transfer markets ignited this private debt boom. Is that a new area of growth for Apollo. Okay.I'm not a big football guy. And I saw the headline this morning and I know get asked about it. It's it is an area we're involved in, in player financing.You know, 5 billion is is a big number. It's probably not gigantic by the scale of, you know, the credit markets and our activities in Europe. But certainly it's an are ...

Federal Reserve Policy - The market anticipates the Federal Reserve (Fed) to potentially cut rates, influenced by conflicting signals from inflation and employment data [2][3] - There is internal debate within the Federal Open Market Committee (FOMC) regarding whether to prioritize inflation or growth concerns [3][4] - The market is closely watching for guidance from the Fed chair, as his stance will be critical in shaping committee consensus [9][10][11] - Dissent within the FOMC is growing, potentially leading to a divided committee and a challenging press conference for the chair [11][12][13][14][15] Inflation and Market Expectations - The market is pricing in inflation above the Fed's 2% target in one year's time, as indicated by one-year ahead inflation swaps trading at 33% [11] - The market has adjusted its expectations regarding the number of rate cuts, initially anticipating three cuts but now expecting closer to two [18] Economic Outlook and Trade - Concerns exist about a potential trade-related slowdown, particularly in the context of ongoing trade wars [20] - Simulations suggest that raising the effective tariff rate from 3% to 18% could decrease GDP by 07%, but not necessarily lead to a recession [21][22]

RT Token Terminal 📊 (@tokenterminal)🏦⛓️ ICYMI: BlackRock, Franklin Templeton, and Apollo are building on @Aptos. https://t.co/W9DtYXDm7u ...

🏦⛓️ ICYMI: BlackRock, Franklin Templeton, and Apollo are building on @Aptos. https://t.co/W9DtYXDm7u ...

BlackRock. Hamilton Lane. Apollo. Ondo. Circle.The institutional-grade asset ecosystem on Sei is accelerating.Markets Move Faster on Sei. ($/acc) ...